Douleurs neuropathiques: contexte, nouveaux outils, nouveaux medicaments. [Neuropathic pains: background, new tools, new drugs]

Détails

Ressource 1Télécharger: RMS_43_2812.pdf (118.98 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_36CDEFBFE35E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Douleurs neuropathiques: contexte, nouveaux outils, nouveaux medicaments. [Neuropathic pains: background, new tools, new drugs]
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Kuntzer T., Decosterd I.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
11/2005
Peer-reviewed
Oui
Volume
1
Numéro
43
Pages
2812-6
Langue
français
Notes
English Abstract Journal Article Review --- Old month value: Nov 30
Résumé
Neuropathic pains are frequent with better understood underlying mechanisms. The introduction of a new questionnaire, named DN4 (neuropathic pain 4 questions) will certainly be useful to prevent persistent pain. Here we describe current approaches to diagnosis and pharmacological treatments. Antidepressants, anticonvulsants, opioids and topical local anesthetics are part of the evidence-based approach, alone or in combination. The choice of the drug is based on the type of pain, a predominantly diffused pain being firstly treated with tricyclic antidepressants, whereas paroxysmal and localized pain being more adequately treated with anti-epileptics. Pregabaline, the newest anticonvulsant launched in the Swiss market, appears to be effective as a treatment of painful diabetic polyneuropathy and postherpetic neuralgia.
Mots-clé
Anesthetics/therapeutic use Anticonvulsants/*therapeutic use Antidepressive Agents/*therapeutic use Humans Narcotics/therapeutic use Nervous System Diseases/*complications Pain/*drug therapy/*etiology
Pubmed
Création de la notice
25/01/2008 12:43
Dernière modification de la notice
01/11/2024 14:06
Données d'usage